Applied DNA Sciences (APDN)
(Delayed Data from NSDQ)
$3.22 USD
+0.14 (4.55%)
Updated May 14, 2024 03:59 PM ET
After-Market: $3.10 -0.12 (-3.73%) 6:28 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
APDN 3.22 +0.14(4.55%)
Will APDN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for APDN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for APDN
Applied DNA Sciences (APDN) Reports Q2 Loss, Tops Revenue Estimates
Clear Secure (YOU) Q1 Earnings and Revenues Top Estimates
APDN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Rockwell Automation (ROK) Q2 Earnings and Revenues Surpass Estimates
Allegion (ALLE) Q1 Earnings Surpass Estimates
Is Applied DNA Sciences (APDN) Outperforming Other Industrial Products Stocks This Year?
Other News for APDN
Why Alcon Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
12 Health Care Stocks Moving In Monday's Intraday Session
Applied DNA Sciences announces presentation on use of Linea DNA
Institute of Hematology and Blood Transfusion (Prague) to Present on Successful Use of Applied DNA's Linea DNATM for the Non-Viral Manufacture of CAR T-Cell Therapy for Refractory AML
LIDR, ELDN and IVP among pre-market losers